Visit the Lenze web site
Click on the advert above to visit the company web site

Product category: Engineering Business News and Views
News Release from: ARC Advisory Group
Edited by the Engineeringtalk Editorial Team on 07 October 2002

Consulting services expand

Request your FREE weekly copy of the Engineeringtalk email newsletter. News about Engineering Business News and Views and more every issue. Click here for details.

ARC Advisory Group has expanded its strategic consulting services to include a team dedicated to the pharmaceutical and biotech industries.

ARC Advisory Group has expanded its strategic consulting services to include a team dedicated to the pharmaceutical and biotech industries This expansion provides services for the issues facing pharmaceutical-biotech clinical research and manufacturing, commercial manufacturing, and suppliers of automation technology

The high financial investment coupled with the diversity of new treatments increases risk and drives the need for industry knowledgeable strategic consulting.

With a 12 to 15 year product development cycle costing over $800 million to bring a single drug to market, companies in this industry have many business, supply chain, and manufacturing issues that are unique.

They require specialized knowledge and expertise in regulatory requirements, automation technology, and business best practices.

New drugs and treatments were made possible by tremendous scientific progress in biotechnology, biochemistry, and genetic engineering.

Global awareness creates a high demand for the latest life improving drugs.

These issues plus the demand for cost containment, a wider variety of affordable drugs, and increasing regulatory costs, are redefining the health care industry.

This includes closer relationships with suppliers, closer collaboration from drug development through clinical trials and commercial manufacturing, and the use of leading edge technologies to improve the entire business supply chain and manufacturing processes.

ARC is unique in its ability to provide strategic consulting to pharmaceutical companies so they can better respond to their changing market requirements.

ARC's Pharmaceutical-BioTech Consulting Practice covers logistics, supply chain, automation, control system integration, batch management, regulatory requirements, advanced control, and optimization applications.

Supplier and users alike are focused on the FDA's 21 CFR Part 11 requirements and new drug validation.

Manufacturers in the FDA-regulated industries get a better understanding of currently available technologies and services to help them determine how to meet 21 CFR Part 11 requirements and speed validation.

ARC Advisory Group: contact details and other news
Email this article to a colleague
Register for the free Engineeringtalk email newsletter
Engineeringtalk Home Page

Search the Pro-Talk network of sites

Visit the Lenze web site